An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants
Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- CN00103
-
Beijing, China
- CN00104
-
Beijing, China
- CN00106
-
Beijing, China
- CN00111
-
Beijing, China
- CN00112
-
Beijing, China
- CN00114
-
Beijing, China
- CN00115
-
Beijing, China
- CN00127
-
Changsha, China
- CN00121
-
Hangzhou, China
- CN00107
-
Nanjing, China
- CN00110
-
Nanjing, China
- CN00117
-
Shanghai, China
- CN00102
-
Shanghai, China
- CN00105
-
Shanghai, China
- CN00108
-
Shanghai, China
- CN00113
-
Shanghai, China
- CN00126
-
Suzhou, China
- CN00119
-
Tianjin, China
- CN00125
-
Wenzhou, China
- CN00118
-
Wuhan, China
- CN00109
-
Xi'an, China
- CN00124
-
-
-
-
-
Hong Kong, Hong Kong
- HK00402
-
-
-
-
-
Anyang, South Korea
- KR00214
-
Busan, South Korea
- KR00205
-
Busan, South Korea
- KR00207
-
Cheongju-si, South Korea
- KR00212
-
Daegu, South Korea
- KR00203
-
Daejeon, South Korea
- KR00213
-
Incheon, South Korea
- KR00201
-
Seongnam-si, South Korea
- KR00202
-
Seoul, South Korea
- KR00204
-
Seoul, South Korea
- KR00206
-
Seoul, South Korea
- KR00208
-
Seoul, South Korea
- KR00209
-
Seoul, South Korea
- KR00210
-
Seoul, South Korea
- KR00211
-
Seoul, South Korea
- KR00215
-
-
-
-
-
Kaohsiung City, Taiwan
- TW00309
-
Taichung, Taiwan
- TW00302
-
Taichung, Taiwan
- TW00303
-
Tainan City, Taiwan
- TW00307
-
Tainan City, Taiwan
- TW00308
-
Taipei, Taiwan
- TW00301
-
Taipei, Taiwan
- TW00304
-
Taipei, Taiwan
- TW00306
-
Taoyuan, Taiwan
- TW00305
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
- Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy
- Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bone disease
- No prior treatment with cytotoxic chemotherapy
- Asymptomatic or mildly symptomatic from prostate cancer
Exclusion Criteria:
- Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment
- Known or suspected brain metastasis or active leptomeningeal disease
- History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer
- History of seizure including febrile seizure or any condition that may predispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Enzalutamide
Participants received 160 mg of enzalutamide orally once a day during double blind period until Prostate-Specific Antigen (PSA) progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
Eligible participants who received enzalutamide during double blind and who provided consent to take part in open-label period continued to receive 160 mg of enzalutamide in open-label period orally once a day until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
|
Oral
Other Names:
|
|
Experimental: Placebo
Participants received enzalutamide matching placebo orally once a day during double-blind period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
|
Oral
|
|
Experimental: Placebo followed by Enzalutamide
Eligible participants who received enzalutamide matching placebo during double-blind period and who provided consent to take part in open-label period, received 160 mg of enzalutamide orally once a day during open-label period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
|
Oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Prostate-specific Antigen (PSA) Progression
Time Frame: From the date of randomization to PSA progression median follow-up time is 6.47 months for enzalutamide and 2.99 months for placebo
|
The time to Prostate Specific Antigen (PSA) progression was defined as the time from randomization to the PSA progression.
The PSA progression was defined according to the consensus guidelines of Prostate Cancer Clinical Trials Working Group 2 (PCWG2).For participants with PSA decline at Week 13, the PSA progression date was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir, which would be confirmed by a second consecutive value obtained 3 or more weeks later.
For participants with no PSA decline at Week 13, the PSA progression date was defined as the date when a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline was documented, which was confirmed by a second consecutive value 3 or more weeks later.
Time to PSA progression was estimated using the Kaplan-Meier method.
Participants without confirmed PSA progression were censored.
|
From the date of randomization to PSA progression median follow-up time is 6.47 months for enzalutamide and 2.99 months for placebo
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of Overall Survival
Time Frame: From the date of randomization to deaths from any cause median follow-up time is 42.32 months for enzalutamide and 26.81 months for placebo
|
Duration of overall survival was defined as the time from the randomization to deaths from any cause.
For participants who were alive at the time of the data analysis, overall survival time was censored to the last know date the participants were known to be alive.
|
From the date of randomization to deaths from any cause median follow-up time is 42.32 months for enzalutamide and 26.81 months for placebo
|
|
Duration of Radiographic Progression-free Survival (rPFS) Based on Independent Central Review Facility Assessment
Time Frame: From the date of randomization to the rPFS event (deaths from any cause and radiographic disease progression) median follow-up time is 5.55 months for enzalutamide and 3.71 months for placebo
|
Duration of Radiographic Progression-free Survival (rPFS) was defined as the time from randomization to the rPFS event (deaths from any cause and radiographic disease progression).
Radiographic disease progression is defined by RECIST 1.1 for soft tissue disease, or PCWG2 for bone lesions.
If a participant met the criteria for more than 1 censoring rule, they were censored with the earliest censoring date.
The radiographic progression date was the first date when progression definition was met, not confirmed.
|
From the date of randomization to the rPFS event (deaths from any cause and radiographic disease progression) median follow-up time is 5.55 months for enzalutamide and 3.71 months for placebo
|
|
Time to First Skeletal-Related Event
Time Frame: From the date of randomization to the first skeletal-related event median follow-up time is 7.39 months for enzalutamide and 5.29 months for placebo
|
Time to first skeletal-related event (SRE) was defined as the time from randomization to the first skeletal-related event, defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of anti-neoplastic therapy to treat bone pain.
Participants who have not had a SRE at the time of the analysis were censored at their last assessment indicating no evidence of SRE.
|
From the date of randomization to the first skeletal-related event median follow-up time is 7.39 months for enzalutamide and 5.29 months for placebo
|
|
Time to Initiation of Cytotoxic Chemotherapy
Time Frame: From the date of randomization to initiation of cytotoxic chemotherapy median follow-up time is 7.39 months for enzalutamide and 5.19 months for placebo
|
Time to initiation of cytotoxic chemotherapy was defined as the time from randomization to initiation of cytotoxic chemotherapy.
It included only therapies for prostate cancer.
When multiple cytotoxic chemotherapies were initiated, the first chemotherapy was used to determine the time to event.
Participants who did not start cytotoxic chemotherapy at the time of analysis data cutoff were censored at the date of their last assessment indicating no evidence of cytotoxic chemotherapy usage.
|
From the date of randomization to initiation of cytotoxic chemotherapy median follow-up time is 7.39 months for enzalutamide and 5.19 months for placebo
|
|
Number of Participants With Confirmed Best PSA Response (≥50% Decrease From Baseline)
Time Frame: From baseline to the lowest post-baseline PSA result median treatment duration is 6.60 months for enzalutamide and 3.70 months for placebo
|
Best PSA response was defined as as ≥50% reductions in PSA level from baseline to the lowest post-baseline PSA result as determined by the central laboratory, with a consecutive assessment conducted at least 3 weeks later to confirm the PSA response.
Only participants who had both baseline and post-baseline assessments were included in the analysis.
|
From baseline to the lowest post-baseline PSA result median treatment duration is 6.60 months for enzalutamide and 3.70 months for placebo
|
|
Best Overall Soft Tissue Response
Time Frame: From the date of randomization median treatment duration is 6.60 months for enzalutamide and 3.70 months for placebo
|
Participants with measurable soft tissue disease at screening visit (i.e., at least one target lesion per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) who have an objective response (complete response (CR) or partial response (PR)) during the study were included in the best overall soft tissue response assessment.
The best overall soft tissue response was based on the investigator assessment using RECIST 1.1.
CR was defined as complete resolution of all attributable clinical symptoms and physical findings.
PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.
|
From the date of randomization median treatment duration is 6.60 months for enzalutamide and 3.70 months for placebo
|
|
Time to Maximum Concentration (Tmax) of Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time Frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
|
From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
|
|
|
Maximum Observed Plasma Concentration During the First 24 Hours After Dosing (Cmax) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time Frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
|
From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
|
|
|
AUC From the Time of Dosing to 24 h After Dosing (AUC24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time Frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
|
From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
|
|
|
Concentration 24 h After Dosing (C24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time Frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
|
N is the number of participants with available data at this time point.
|
From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
|
|
Observed Plasma Concentration in Predose Samples Obtained During Multiple-dose Administration of Minimum Concentration (Plasma Concentration at Pre Dose) (Cmin) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time Frame: From the date of randomization up to Days 2, 3, 8, 22, 29, 43, 57, 85, 86, 113, 141 and 169
|
N is the number of participants with available data at this time point.
|
From the date of randomization up to Days 2, 3, 8, 22, 29, 43, 57, 85, 86, 113, 141 and 169
|
|
Apparent Total Systemic Clearance After Multiple Dosing (CL/F) Enzalutamide, M1,M2 and Enzalutamide Plus M2 (For Unchanged Enzalutamide Only)
Time Frame: From the date of randomization up to Multiple Dosing Day 85
|
From the date of randomization up to Multiple Dosing Day 85
|
|
|
Peak-Trough Ratio (PTR) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time Frame: From the date of randomization up to Multiple Dosing Day 85
|
From the date of randomization up to Multiple Dosing Day 85
|
|
|
AUC From the Time of Dosing to the Start of the Next Dosing Interval (AUCtau) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time Frame: From the date of randomization up to Multiple Dosing Day 85
|
From the date of randomization up to Multiple Dosing Day 85
|
|
|
Number of Participants With Adverse Events (AE)
Time Frame: From first dose on Day 1 until 28 days after the last dose of study drug, or one day before the date of initiation of cytotoxic chemotherapy or an investigational agent for treatment of prostate cancer, whichever comes first, up to 123 months and 24 days
|
An AE was defined as any untoward medical occurrence, temporally associated with use of medicinal product, whether considered related to medicinal product.
AE could therefore be any unfavorable & unintended sign, symptom, or disease temporally associated with use of a medicinal product.
An AE was considered serious if, results in death; is life-threatening; results in persistent disability; results in congenital anomaly; requires inpatient hospitalization; or leads to prolongation of hospitalization; other medically important events.
TEAE was defined as AE occurring from time of study drug administration on Day 1 until follow-up visit (28 days after last dose, or one day before date of initiation of cytotoxic chemotherapy or an investigational agent, whichever comes first).
AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal.
|
From first dose on Day 1 until 28 days after the last dose of study drug, or one day before the date of initiation of cytotoxic chemotherapy or an investigational agent for treatment of prostate cancer, whichever comes first, up to 123 months and 24 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Central Contact, Astellas Pharma Inc
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Neuromuscular Diseases
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Genetic Diseases, X-Linked
- Spinal Cord Diseases
- Motor Neuron Disease
- Muscular Atrophy, Spinal
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Prostatic Neoplasms
- Bulbo-Spinal Atrophy, X-Linked
- enzalutamide
Other Study ID Numbers
Other Study ID Numbers
- 9785-CL-0232
- CTR20140131 (Registry Identifier: ChinaDrugTrials.org.cn)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.